Belgian Banks Stock News

Why Anheuser-Busch InBev (ENXTBR:ABI) is Back on Investor Radar Anheuser-Busch InBev (ENXTBR:ABI) has drawn fresh attention after recent share price moves and steady longer term returns, prompting investors to reassess how its global beer and beverage footprint lines up with current valuations. See our latest analysis for Anheuser-Busch InBev. Recent trading has been mixed, with a 5.32% 1 month share price return and a 14.26% year to date share price return contributing to a 10.01% 1 year...

As European markets face heightened geopolitical tensions and economic uncertainties, traditionally defensive sectors such as utilities and telecoms have shown resilience, with the pan-European STOXX Europe 600 Index recently experiencing a decline. In this environment, dividend stocks can offer a measure of stability and potential income for investors seeking to navigate these challenging times.

Q1 2026 earnings snapshot and how the story is evolving Xior Student Housing (ENXTBR:XIOR) has opened 2026 with Q1 revenue of €58.6 million and basic EPS of €1.04, putting fresh numbers behind a share price of €27.45. Over the recent reporting periods, revenue has ranged from €50.6 million to €62.5 million per quarter, while basic EPS has swung between a small quarterly loss of €0.01 and a high of €1.04, giving investors a clear view of how sensitive per share results have been to shifts in...

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...

UCB (ENXTBR:UCB) is presenting new clinical and real-world data at the American Academy of Neurology Annual Meeting. The updates cover epileptic encephalopathies, prolonged seizures, and generalized myasthenia gravis. Key datasets focus on fenfluramine in Dravet and Lennox Gastaut syndromes and on zilucoplan and rozanolixizumab in myasthenia gravis. Additional findings address patient and caregiver quality of life, healthcare resource use, and treatment patterns. For investors following...

Anheuser-Busch InBev commits $600 million to expand U.S. investment and workforce development. Plan includes new technical training centers and a large scale upskilling program across manufacturing roles. Company also expands its veteran hiring initiatives to support transitions into private sector careers. Anheuser-Busch InBev, listed as ENXTBR:ABI, is putting fresh attention on its U.S. footprint with this $600 million package focused on facilities and people. The company’s shares...

argenx (ENXTBR:ARGX) drew attention after presenting new VYVGART and neuromuscular pipeline data at the 2026 American Academy of Neurology meeting, together with an ongoing FDA priority review for a supplemental label expansion. See our latest analysis for argenx. The recent clinical updates and FDA priority review arrive after a 17.5% 1 month share price return and a year to date share price decline of 5.3%, while the 1 year total shareholder return is 28.9% and the 5 year total shareholder...

Cofinimmo (ENXTBR:COFB) opened Q1 2026 with total revenue of €87.3 million and basic EPS of €1.41, while trailing twelve month revenue stood at €382.3 million and EPS at €5.32, setting a clear earnings season snapshot for investors. Over recent quarters the company has seen revenue move between €86.8 million and €128.8 million with quarterly EPS ranging from €0.58 to €1.69, giving a fuller picture of how the current print fits into its recent history. Taken together, the latest numbers point...

As European markets experience a positive uptick, with the STOXX Europe 600 Index rising by 1.91% amid easing geopolitical tensions and corporate earnings reports, investors are closely watching dividend stocks for potential stability and income in an uncertain economic climate. A good dividend stock in this environment is typically characterized by consistent payouts and strong financial health, offering a reliable income stream even as broader market conditions fluctuate.

If you are wondering whether argenx is priced attractively or already reflecting high expectations, especially after a strong run in recent years, this article explains what the current share price might indicate about value. argenx recently closed at €707.6, with returns of 4.5% over 7 days, 21.0% over 30 days, 35.0% over 1 year, 100.6% over 3 years and 187.3% over 5 years. Year to date, the stock shows a 2.2% decline. Recent headlines around argenx have kept attention on the company and...

What recent performance tells you about Anheuser-Busch InBev (ENXTBR:ABI) Anheuser-Busch InBev (ENXTBR:ABI) has drawn fresh attention after recent share price moves, with the stock showing positive returns over the past month and the past 3 months, alongside solid reported revenue and net income figures. See our latest analysis for Anheuser-Busch InBev. Beyond the recent uptick, the 1 month share price return of 9.16% and year to date share price return of 18.71% suggest momentum has been...

Groupe Bruxelles Lambert (ENXTBR:GBLB) just reported full year 2025 results, posting sales of €6,221.7 million and a net loss of €625.4 million, a swing from net income in the prior year. See our latest analysis for Groupe Bruxelles Lambert. The earnings swing to a net loss comes as the share price has still delivered a 1 month share price return of 4.7% and a 1 year total shareholder return of 25.8%, suggesting that investors may be reassessing long term prospects rather than reacting only...

BGL BNP Paribas (ENXTBR:009789111) has released its full year 2025 results, reporting net income of €514.5 million compared to €477.9 million a year earlier. This provides investors with fresh data to reassess the stock. See our latest analysis for BGL BNP Paribas. The share price is currently €89.0, and the flat short-term share price returns sit alongside a 1-year total shareholder return of 0.00%. This suggests recent earnings news may not yet have shifted market expectations in a clear...

Recently, argenx reported the completion of a key CIDP switch study for its efgartigimod therapy, marking a meaningful clinical milestone in its autoimmune portfolio. This progress in CIDP strengthens the case for efgartigimod as a potentially broader platform therapy across neuromuscular autoimmune indications. Next, we will examine how completion of the CIDP switch study might influence argenx’s investment narrative and outlook for efgartigimod. Capitalize on the AI infrastructure...

Fagron (ENXTBR:FAGR) put acquisitions back in focus in its Q1 2026 trading update, pairing 10% topline growth with confirmation that recent deals, including Pharmavit in the Netherlands, are being integrated as planned. See our latest analysis for Fagron. The share price sits at €22.5, with a 3.45% year to date share price return and a 17.69% one year total shareholder return, which hints that investors are gradually warming to Fagron's growth and acquisition story. If Fagron's acquisition...

Solvac S.A.'s ( EBR:SOLV ) solid earnings announcement recently didn't do much to the stock price. Our analysis...

Why Azelis Group is on investors’ radar Azelis Group (ENXTBR:AZE) has caught investor attention after a recent share price move, with the stock showing a mix of short term gains and longer term weakness that raises fresh questions about its current valuation. See our latest analysis for Azelis Group. The recent rally, including a 23.88% 30 day share price return and 5.37% 7 day share price return to €9.415, comes against a much weaker backdrop, with a 36% 1 year total shareholder return...

BlackRock, Inc. disclosed that its direct voting rights in Umicore (ENXTBR:UMI) moved above the 5% threshold, then later fell back below 5%, within a short period. The changes were reported through regulatory filings, highlighting shifts in a major institutional investor's position in the company. Crossing the 5% level triggers mandatory disclosure rules, which can draw market attention to institutional ownership in Umicore. Umicore operates in materials technology and recycling, with...

Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be...

Norse Wind vessel puts DEME Group (ENXTBR:DEME) in focus DEME Group (ENXTBR:DEME) has drawn fresh investor attention after christening the Norse Wind, a new offshore wind installation vessel equipped with a 3,200-tonne crane and a hybrid power system. The ship is built to install larger next generation turbines and operate in harsher offshore conditions. Its hybrid setup targets more than 70% emission reductions. Norse Wind already carries long term contracts for major European offshore wind...

Why Solvay (ENXTBR:SOLB) Is On Investors’ Radar Today Solvay (ENXTBR:SOLB) has caught investor attention after recent share price moves, with the stock closing at €27.18 and showing mixed return patterns over the past week, month and past 3 months. See our latest analysis for Solvay. Recent trading has been steady rather than dramatic, with a 6.8% 1 month share price return and a slightly negative year to date move, while the 5 year total shareholder return of 58.6% reflects a stronger longer...

As European markets experience a boost in sentiment due to hopes of a shorter Middle East conflict, indices like the STOXX Europe 600 and Germany's DAX have shown notable gains. In this environment, identifying stocks that may be trading below their estimated value can offer opportunities for investors looking to capitalize on potential market inefficiencies.

Onward Medical (ENXTBR:ONWD) has reported its FY 2025 first half with revenue of €1.2 million, a basic EPS loss of €0.47, and net income loss of €21.2 million, setting a clear tone for another year focused on growth over profitability. The company has seen revenue move from €0.2 million in the first half of 2024 to €1.5 million in the second half of 2024 and €1.2 million in the first half of 2025. Basic EPS has shifted between losses of €0.53, €0.32, and €0.47 over the same periods,...

Syensqo (ENXTBR:SYENS) has wrapped up FY 2025 with fourth quarter revenue of €1,384 million and basic EPS of a €1.61 loss, while the trailing twelve months show revenue of €5,969 million and basic EPS of a €0.85 loss. Over recent quarters, revenue has moved from €1,662 million in Q4 2024 to €1,678 million in Q1 2025, €1,639 million in Q2 2025, €1,558 million in Q3 2025, and €1,384 million in Q4 2025, with EPS swinging between a €1.28 loss and a €0.49 gain before landing at a €1.61 loss this...